Delivery Order SPE2DB24D1205-SPE2DB25FCZLU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. The contract is non-competitive, firm fixed price delivery order with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price delivery order, valued at $4,687.18, carries an ultimate completion date of August 21, 2025, and represents a non-competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract is not set aside for any socioeconomic category and is scheduled for completion by August 12, 2025. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment...
- The Defense Logistics Agency awarded a $2,343.59 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen auto-injectors, with an ultimate completion date of August 25, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award issued on August 4, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE (tezepelumab) is a biologic medication used for the treatment of severe asthma,...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract with an ultimate completion date of September 3, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for Tezspire 210 mg/1.91 mL pen auto-injectors valued at $4,687.18, with completion scheduled for August 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract is to be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 22, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a specialty pharmaceutical treatment used in respiratory and immunological applications, reflecting the...
- The Defense Logistics Agency (DLA) awarded a $14,061.54 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL auto-injection pens. The contract, issued under firm fixed pricing with no set-aside designation, is scheduled for completion by September 3, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Tezspire is a biologic medication used in the treatment of severe asthma and chronic rhinosinusitis...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a standard...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZLUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of TEZSPIRE 210 mg/1.91 ml auto-injector pens valued at $4,687.18. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The contract requires completion by September 3, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE (tezepelumab) is a specialty biologic pharmaceutical used in the treatment of severe asthma, reflecting the Defense Logistics Agency's continued procurement of specialized pharmaceutical products for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger $999.999 billion indefinite delivery contract with DLA Troop Support Medical (designated SPE2DX), which runs through December 2026 and serves as a comprehensive global pharmaceutical support vehicle. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies an extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide, including services to the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/12/25 |